(CercleFinance.com) – GSK announced on Wednesday that it has completed the acquisition of Bellus Health, a Canadian biopharmaceutical company specializing in the treatment of chronic refractory cough (CCR), for an amount of two billion dollars.
The operation, initially announced last February, will allow the British laboratory to get its hands on camlipixant, an experimental drug currently in phase III for the treatment of adult patients with CRC.
According to GSK, some 28 million patients suffer from chronic cough, an indication for which there is currently no approved medicine in the United States or Europe.
The biopharmaceutical group expects the acquisition to be accretive in terms of its earnings per share (EPS) from 2027, with a significant contribution to the level of its sales from 2031.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
This is a Smartvoice article: see legal notice